ConferencePoster
 (2024)

Safety and efficacy of vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in previously untreated advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II KEYVIBE-005 study

Toullec, C; Seo, C; Robinson, AG; Chou, HH; Salman, P; Ghiringhelli, F; Ozyilkan, O; Rojas, CI; Sendur, M.A.N; Le Tourneau, C et al